N-arachidonoyl-phenol-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-arachidonoyl-phenol-amine
• 英文别名: N-arachidonoylaminophenol；n-Arachidonoylphenolamine；(5Z,8Z,11Z,14Z)-N-(2-hydroxyphenyl)icosa-5,8,11,14-tetraenamide
• 化学式: C₂₆H₃₇NO₂
• 分子量: 395.585
• InChiKey: QVZOWUCARQBOOX-DOFZRALJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.2
• 重原子数：
  29
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  花生四烯酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 苯 为溶剂， 反应 1.25h， 生成 N-arachidonoyl-phenol-amine
  参考文献：
  名称：

  内源性大麻素配体花生四烯基乙醇酰胺的头基类似物。

  摘要：

  合成了内源性大麻素的几种类似物花生四烯基乙醇酰胺（anandamide），以研究乙醇酰胺首基的结构要求。通过标准的受体结合测定法，使用tri化的CP-55,940作为放射性配体，评估了类似物的CB1受体亲和力，并与Kan为78 nM的anandamide进行了比较。用硫原子取代酰胺羰基氧对CB1亲和力有不利影响。anandamide和（R）-methanandamide的硫代类似物对CB1的亲和力很弱。还显示了酰胺氮的次要性质对于亲和力很重要，表明酰胺NH与受体之间可能存在氢键相互作用。在头部基团中引入酚部分会导致受体亲和力的损失，除非在the基氮和酚之间引入亚甲基间隔基。还使用小鼠脾制剂测试了一组类似物对CB2受体的亲和力，发现它们对CB2位点的亲和力低。值得注意的是，anandamide和（R）-methanandamide对CB1受体表现出很高的选择性。总体而言，此处提供的数据表明，

  DOI：

  10.1021/jm960152y

文献信息

• Compositions and methods for ameliorating pain and reducing fever
  申请人：The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

  公开号：US11007199B2

  公开（公告）日：2021-05-18

  This invention is directed to compositions, methods and kits that can be used for the treatment or amelioration of pain and fever.

  本发明涉及可用于治疗或改善疼痛和发烧的组合物、方法和试剂盒。
• COMPOSITION AND METHODS TO IMPROVE STABILITY, DOSING, PHARMACODYNAMICS AND PRODUCT SHELF LIFE OF ENDOCANNABINOIDS, PHYTOCANNABINOIDS AND SYNTHETIC CANNABINOIDS DELIVERED BY NASAL INHALER
  申请人：Willinsky, Michael

  公开号：EP3247402A1

  公开（公告）日：2017-11-29
• Pharmaceutical combination for the treatment of pain (acute or chronic), as powerful as a narcotic medication but non narcotic ,therefore very unlikely to create addiction
  申请人：Benoit Jacques

  公开号：US20100261686A1

  公开（公告）日：2010-10-14

  The management of pain specially chronic pain often requires the use of opiate like medications which have a large number of undesirable effects, the most important one being habituation and addiction. The present invention consists of an integrated combination of medications acting through different mechanisms that are just as powerful as opiates in the management of pain without many of the undesirable side effects such as habituation and addiction.
• Method for predicting autism spectrum disorders by cannabinoid and cannabinoid receptor expression
  申请人：Schultz Stephen T.

  公开号：US20120225015A1

  公开（公告）日：2012-09-06

  The inventive method relates to a method for the determination of susceptibility or diagnosis of autism or autism spectrum disorders. Diagnosis or determination of susceptibility determinations are predicated on quantitative analysis of endocannibinoid levels or endocannibinoid receptor expression.
• COMPOSITION AND METHODS TO IMPROVE STABILITY, DOSING, PHARMACODYNAMICS AND PRODUCT SHELF LIFE OF ENDOCANNABINOIDS, PHYTOCANNABINOIDS AND SYNTHETIC CANNABINOIDS DELIVERED BY NASAL INHAER
  申请人：Willinsky Michael

  公开号：US20180000727A1

  公开（公告）日：2018-01-04

  An inhaler-delivery-device-packaged homogenate of solid heterogeneous-lipid particulates carrying lipophilic cannabinoid receptor agonists and/or antagonists, wherein the solid heterogeneous-lipid particles comprises: one (or more) lipid(s) whose melting point(s) is (are) substantially above room temperature; in combination with, one (or more) lipid(s) whose melting point(s) is (are) substantially less than room temperature.